Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1-γ-Positive Dermatomyositis.

Chih-Feng Wu, Wan-Ting Chen, Yen-Lin Chen, Feng-Cheng Liu

Open access · goldAbstract readCase Reports

In one paragraph

Article in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 41% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Chih-Feng WuSchool of Medicine, National Defense Medical Center, Taipei 114, Taiwan.

Wan-Ting ChenSchool of Medicine, National Defense Medical Center, Taipei 114, Taiwan.ORCID 0000-0002-5422-5032

Yen-Lin ChenDepartment of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan.ORCID 0000-0002-6381-4269

Feng-Cheng LiuSchool of Medicine, National Defense Medical Center, Taipei 114, Taiwan.

Tri-Service General Hospital · TWNational Defense Medical Center · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An increase in skin-related autoimmune disorders has been reported as an adverse effect of coronavirus disease 2019 (COVID-19) vaccines. We present the case of a 90-year-old Taiwanese female who was newly diagnosed with anti-transcription intermediary factor 1-gamma (anti-TIF1-γ)-positive dermatomyositis (DM) after receiving a second dose of the AstraZeneca COVID-19 vaccine. Under treatment with prednisolone and monoclonal antibody therapy of abatacept, her skin lesions improved, and her muscle power increased. The serum creatinine phosphokinase level decreased from 4858 to 220 U/L, and the anti-TIF1-γ antibody titer decreased from 202 to 99. Flow cytometry data showed an increase in T cells, while NK cells, B cells (CD19), and plasma blasts all decreased. These findings suggest that standard DM treatment might be beneficial to patients with COVID-19 vaccine-induced DM.

Indexed as

COVID-19 VaccinesDermatomyositisTranscription FactorsAged, 80 and overAntibodies, MonoclonalAutoantibodiesChAdOx1 nCoV-19COVID-19FemaleHumansPrednisoloneSARS-CoV-2Antibodies, MonoclonalAutoantibodiesChAdOx1 nCoV-19COVID-19 VaccinesPrednisoloneTranscription FactorsTRIM33 protein, humanCOVID-19 vaccinedermatomyositisimmunotherapy

Identifiers

PMID37763807

DOI10.3390/medicina59091688

PMCPMC10535214

OpenAlexW4386933657

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.